Moderna has created a Chief Operating Officer role and named Juan Andres to fill it, effective October 5, 2026. Andres previously led Moderna’s manufacturing expansion through the COVID-19 vaccine surge before retiring in 2023. The move signals that the company is preparing for the operational demands of launching intismeran autogene, its jointly developed cancer immunotherapy with Merck, following positive Phase 3 results, while managing an expanded infectious disease franchise that now includes five approved vaccines.
The appointment comes as Moderna faces the operational challenge of transitioning from pandemic-driven revenue to a diversified portfolio. The company reported FY2025 revenue decline of 39.9 percent against the prior year, with operating margin at negative 158.1 percent. Andres will oversee manufacturing and report to CEO Stéphane Bancel. Jerh Collins, who served as Chief Technical Operations and Quality Officer for four years, is retiring. Collins joined Moderna in October 2022 and helped establish the manufacturing model to support intismeran autogene during his tenure.
What it means
The creation of a dedicated COO role reflects a structural shift at Moderna: the company is moving from a single-product (COVID vaccine) operation toward a multi-program manufacturer. Andres’ prior experience building out Moderna’s global manufacturing network during the pandemic suggests the company expects intismeran autogene to require significant production capacity once it launches. The announcement does not provide a timeline for intismeran autogene’s commercial availability or manufacturing scale targets, leaving open the question of how quickly Moderna expects to ramp production and what capital investment that will require.
The appointment of someone with deep institutional knowledge of Moderna’s operations, rather than an external hire, suggests confidence in the existing manufacturing infrastructure. However, the negative operating margin in FY2025 indicates the company is still burning cash as it pivots away from pandemic revenues. Andres’ mandate to “drive focus, prioritization and execution” across the company hints at potential operational inefficiencies that need addressing as the revenue base shrinks and diversifies.
Collins’ retirement after four years is routine succession planning, though the timing coincides with the company’s shift toward oncology and endemic vaccines. The document does not disclose whether Collins’ departure was planned or prompted by the COO restructuring, nor does it address whether the manufacturing model Collins established for intismeran autogene is complete or still in development.
What to watch
Moderna’s next quarterly earnings report will show whether the company has begun to stabilize revenue decline and whether operating margins are improving as the manufacturing footprint adjusts to endemic vaccine demand. The intismeran autogene regulatory timeline and any manufacturing capacity announcements will clarify whether Andres’ return is preparation for near-term launch or longer-term scaling.
Source: the company’s 8-K filed 2026-09-30 with the SEC.
For the standing yardsticks on Moderna: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Moderna.
